Efficacy of Nasal High Flow therapy on the coordination between breathing and swallowing of saliva during daytime nap in COPD patients.

JRCT ID: jRCTs072200014

Registered date:21/05/2020

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: COPD
• Date of first enrollment: 21/05/2020
• Target sample size: 15
• Study type: Interventional
• Intervention(s): NHF intervention

Outcome(s)

• Primary Outcome: Rate of expiratory phase after swallowing saliva

Secondary Outcome

1) Time-weighted average value of tcpO2 (average partial pressure during observation period)
2) Time-weighted average value of tcpCO2 (average partial pressure during observation period)
3) Time-weighted average value of SpO2 (average oxygen saturation during observation period)
4) Time-weighted average respiratory rate (average respiratory rate during the observation period)

Key inclusion & exclusion criteria

• Age minimum: >= 40age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

The severity of COPD is moderate (GOLD2) or more.
Age: At the time of obtaining consent, an adult patient 40 years or older
Gender: Any
Hospitalization / Outpatient: Outpatient only
Patients who have been given sufficient explanations to participate in this study and have given their full understanding and informed consent from the patient

Exclude criteria

Patients who cannot breathe nose
Patients with a history of pneumothorax
Patients with active malignancy
Patients with acute disease (such as acute myocardial infarction)
Patients currently diagnosed with asthma (Patients who have a history of asthma but are currently diagnosed with COPD are eligible for inclusion.)
Patients who have been diagnosed with obstructive sleep apnea in the past and who are strongly suspected clinically
Patients already using NHF
Patients who are using non-invasive ventilation (NIV) at night
Patients with severe disease of the kidney, liver or circulatory system
Patients who are considered inappropriate by the Principal Investigator
Patients who are positive for the new coronavirus (SARS-CoV-2) PCR test

Related Information

• Primary Sponsor: Ayuse Takao
• Source(s) of Monetary Support: Fisher & Paykel Healthcare Limited,Fisher & Paykel Healthcare Limited